Having just read through some posts on these threads and discussions surrounding comparisons to other biotech stocks, Nasdaq listings and share price performance, with all due respect to fellow posters my own rationale comes from the premise that other biotech stocks cannot be compared to Imugene (IMU ASX). They aren't even beaten favourites, for in reality they aren't even in the race. Therefore to consider how they would or would stack up against IMU in the Nasdaq stakes, or any other for that matter, in my opinion is irrelevant. As is the BOD and managements attempts to compare their stock with others. Many other stocks in the oncology space have had success or are simply endeavouring to sell in the blood cancer market, be it lymphoma or non Hodgkins lymphoma. Like the Her 2 market this is a congested if not crowded space ultimately catering to a small percentage of those diagnosed with cancer. Other stocks including Seagen are focused on ADC's, which are ostensibly a delivery mechanism for often out dated monoclonal antibody technology and chemotherapy. Conversely Imugene holds the silver bullet in their armoury, Vaxinia, designed to infect, replicate in, destroy and eradicate solid tumours in all manner of cancer indications. In short there are no stocks listed on the Nasdaq or anywhere for that matter, with outstanding success rates pre-clinically in treating solid tumours within cancer patients. There are none exhibiting "positive signals" in treating solid tumour patients "in human trials". The ability to treat all cancer indications against the NCI 60 is groundbreaking technology worthy of the "significant breakthrough therapy" tag required to achieve "Fast track approval" by the FDA.
The essence of my argument is that the market, broader public, US influencers and market makers are in the main unaware of Professor Fong's significant breakthrough. They are unaware Imugene are on the cusp of greatness. They are unaware of the rivers of gold applicable to anyone traversing the landscape that is the solid tumour market, for no-one as yet has stood on such hallowed ground. No-one as yet has possessed the keys to unlock the holy grail.
Imugene should have sold a portion or stake in their B cell platform back in in late 2021, prior to Enhertu and other Her 2 success stories, to free up capital in the march toward Vaxinia success. That would have enabled them to continue with a larger Oncarlytics trial and the acquisition of a complimentary allogenic therapy such as Azure Cel, without the need to tap Bell Potter on the shoulder for more funds. Imugene's BOD should have employed a third party to promote a Nasdaq listing the minute signs of necrosis appeared on their nHIS radar in CF33 patents, prior to their FDA IND for Oncarlytics and the recent advancement to a Vaxinia/Keytruda combination. These subsequent milestones would have in and of themselves been recognised by a sophisticated US biotech market for what they are, significant scientific advancements. Particularly when the recognised City of Hope LA Cancer Research Facility is at the helm. Such a listing would have placed Yuman Fong and Imugene's sensational science on the radar of the markets that matter. I realise Imugene's management could be of the belief that the roads to riches shall eventuate as a result of their scientific developments, irrespective of whether the share is trading at 1.7 cents, $1.7 or $17 dollars, and they are probably correct in their assumption. But in reality IMO shareholder suffering need not have occurred had they employed the 3 key components suggested by me in my earlier post(s).
Aside from my own deliberations and at times protestations pertaining to the financial and strategic management of Imugene, their flaws in the communications and marketing department of their business, and their failure to realise any commercial deals to date, I am confident science shall win out in the end. My only regret is that a lot of financial hardship could well have been avoided had management assumed a different path in late 2021 following the combination of Her Vaxx's OSR results and Pravin Kumaya's initial PD1 Vaxx success. But as they say in the classics, that's history. And all is well and good in hindsight. There's no point looking in the rear view mirror at this stage of the equation, we may well crash, again....
DYOR Seek investment advice as and when required Opinions only
Expand
(20min delay)